Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 45, Issue 4, Pages 569-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2019.07.006
Keywords
Myositis; Treatment; Target; Criteria; Autoantibodies; Exercise
Categories
Funding
- Czech Ministry of Health Conceptual Development of Research Organization [00023728]
- Czech Health Research Council [16-33746A]
- Swedish Research Council [2016-01254]
- Swedish Rheumatism Association
- Stockholm County Council
- Karolinska Institutet
- Swedish Research Council [2016-01254] Funding Source: Swedish Research Council
Ask authors/readers for more resources
Major advances have been made in the field of idiopathic inflammatory myopathies (IIM), or myositis, that are likely to facilitate development of new therapeutic strategies that have not yet been applied in this group of diseases. These advances include new classification criteria to better identify the patients with IIM, detection of several new myositis-specific autoantibodies that facilitates subgrouping of patients into more specific clinical phenotypes, development of outcome measures for disease activity, and new response criteria. We have learned from clinical studies that exercise is an important part of treatment and that pharmacologic treatment should be combined with exercise.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available